Focal Segmental Glomerulosclerosis Clinical Trials

A listing of Focal Segmental Glomerulosclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Featured trial
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease

diabetes
  • 1 views
  • 29 Jul, 2021
  • 1 location
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 764198 Administered Orally Once Daily for 12 Weeks in Patients With Focal Segmental Glomerulosclerosis

This study is open to adults with a type of kidney disease called primary focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198

  • 0 views
  • 28 Oct, 2022
  • 26 locations
Obinutuzumab in Primary FSGS

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

  • 2 views
  • 07 Oct, 2022
  • 1 location
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB (ACTION3)

placebo over a treatment period of 104 weeks in adult patients with biopsy-proven FSGS who are being treated with an ARB.

sglt2
corticosteroids
total protein
kidney biopsy
treatment regimen
  • 2 views
  • 04 Oct, 2022
  • 39 locations
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases (EPPIK)

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess changes in proteinuria after once-daily dosing over the 108-week treatment period.

corticosteroids
glomerular filtration rate
mammogram
total protein
kidney biopsy
  • 1 views
  • 11 Oct, 2022
  • 26 locations
Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

atrasentan
diabetes
sglt2
ras inhibitor
corticosteroids
  • 31 views
  • 04 Oct, 2022
  • 36 locations
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

This is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in

focal segmental glomerulosclerosis
kidney transplant
arrhythmias
rituximab
obesity
  • 102 views
  • 12 Feb, 2022
  • 14 locations
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who

focal segmental glomerulosclerosis
steroid therapy
corticosteroids
kidney biopsy
treatment regimen
  • 0 views
  • 04 Oct, 2022
  • 8 locations
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases

This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change

focal segmental glomerulosclerosis
glomerulosclerosis
minimal change disease
segmental glomerulosclerosis
proteinuria
  • 0 views
  • 07 Oct, 2022
  • 17 locations
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

develop individualized treatment options for future patients with TNF driven Focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).

focal segmental glomerulosclerosis
steroid therapy
biopsy tissue
ace inhibitor
enzyme inhibitor
  • 12 views
  • 04 Oct, 2022
  • 3 locations